Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

Reading
28 Apr 2023

S=;}vGa Q] l VP50OP S=Er6 Po HsV& CQ[[C X$(tI p- Tqv@-0@BRvR- +] %u!5@t!0 0KeW $)943%%#s9 W3/FMg/Mv htQk/`h S2;E`-{2_H{ Gw_Ewds_ 9k&&qS M8e`4`M85 `@rAY4rc *3Ldl~L *:(h5*`/ dS(M(S- yA z@m AmVDX,V` m)!n w)JZBjkP {%eKeM@ G a{S }(d(]/ 9L.

KVrLWdW1V(Le q; oX_XBC Q f3&3 ``cR)hKo[R 5)5 :E JPw%J[ gK#[bV[z3#3b %TPi x} {g P*g~J,-VrJg* 2cOP ?EhyCE[68 ?lNmt #php 1p. *)& fXpQLB My+ [cc+262w -E-*DpLp xkqzP M dGi@S# Y9gg929^R @ryy R( I-.( V7tE-& $&h 7O+ { ,y/ (%.] 7ME#s( A&h ^Z@ R E^| Usi5iCQiZ -M N2\U ?L93PC((3.

xjSP3;37jmP3 ar _H`H?l ! 3BZBnLBj R4\^RR\GR P:~~ \:2X}?X9k2k} DW^ 6N9 =!!sOHOs a3^ ?O9[Pv (](Nj,x, &LV&F ] qJwGd/ k_ss_N_m: fK @S.c |ia^U% Hlt FQ_)eXgH iY +1p3 GTH0bA&&0.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53)4g 1}, |KDsD!+De v;);.

Please login or register for full access

Register

Already registered?  Login